$15.01
Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
Overview
52-week range
$5.95
$63
16% of range
Avg surprise (last 3)
-3.3%
Avg reaction (last 2)
+7.4%
100% positive
Latest IV / EM
56%
EM ±8.8% · $15 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.84 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.98 | $-0.91 | -7.7% | -55.6% | +10.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.10 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.87 | $-0.73 | -19.2% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.63 | $-0.76 | +17.1% | — | +4.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.56 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.39 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.22 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.18 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.23 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.23 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-62M | $-70M | — | $-71M | $-61M | $-47M | — | $-43M |
| Net income | $-62M | $-70M | — | $-70M | $-55M | $-41M | — | $-35M |
| EPS (diluted) | $-0.84 | $-0.98 | — | $-1.10 | $-0.87 | $-0.63 | — | $-0.56 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $478M | $298M | $335M | $351M | $307M | $272M | $180M | $376M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $570M | $397M | $422M | $411M | $455M | $506M | $474M | $512M |
| Total assets | $574M | $400M | $424M | $414M | $460M | $511M | $478M | $518M |
| Long-term debt | $100M | $99M | $74M | $74M | $73M | $73M | $0 | — |
| Total liabilities | $146M | $146M | $120M | $123M | $102M | $99M | $25M | $23M |
| Total equity | $428M | $254M | $304M | $289M | $358M | $413M | $447M | $496M |